WO2008073909A2 - Use of peo-pbo block copolymers in ophthalmic compositions - Google Patents

Use of peo-pbo block copolymers in ophthalmic compositions Download PDF

Info

Publication number
WO2008073909A2
WO2008073909A2 PCT/US2007/087012 US2007087012W WO2008073909A2 WO 2008073909 A2 WO2008073909 A2 WO 2008073909A2 US 2007087012 W US2007087012 W US 2007087012W WO 2008073909 A2 WO2008073909 A2 WO 2008073909A2
Authority
WO
WIPO (PCT)
Prior art keywords
poly
composition according
lenses
block copolymer
lens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/087012
Other languages
French (fr)
Other versions
WO2008073909A3 (en
WO2008073909B1 (en
Inventor
Howard Allen Ketelson
Nathaniel D. Mcqueen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Research LLC
Original Assignee
Alcon Research LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT07869093T priority Critical patent/ATE489450T1/en
Priority to HK09108266.1A priority patent/HK1132292B/en
Priority to EP07869093A priority patent/EP2092047B1/en
Priority to PL07869093T priority patent/PL2092047T3/en
Priority to DK07869093.0T priority patent/DK2092047T3/en
Priority to MX2009005533A priority patent/MX2009005533A/en
Priority to BRPI0720063-3A priority patent/BRPI0720063B1/en
Priority to SI200730476T priority patent/SI2092047T1/en
Priority to CA2671376A priority patent/CA2671376C/en
Priority to NZ577237A priority patent/NZ577237A/en
Priority to AU2007333187A priority patent/AU2007333187B2/en
Application filed by Alcon Research LLC filed Critical Alcon Research LLC
Priority to CN2007800456173A priority patent/CN101611127B/en
Priority to DE602007010823T priority patent/DE602007010823D1/en
Priority to JP2009540519A priority patent/JP5124590B2/en
Priority to KR1020097013065A priority patent/KR101378368B1/en
Publication of WO2008073909A2 publication Critical patent/WO2008073909A2/en
Publication of WO2008073909A3 publication Critical patent/WO2008073909A3/en
Publication of WO2008073909B1 publication Critical patent/WO2008073909B1/en
Priority to NO20092036A priority patent/NO340419B1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/0005Other compounding ingredients characterised by their effect
    • C11D3/0078Compositions for cleaning contact lenses, spectacles or lenses
    • AHUMAN NECESSITIES
    • A45HAND OR TRAVELLING ARTICLES
    • A45CPURSES; LUGGAGE; HAND CARRIED BAGS
    • A45C11/00Receptacles for purposes not provided for in groups A45C1/00-A45C9/00
    • A45C11/005Contact lens cases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/14Eye parts, e.g. lenses or corneal implants; Artificial eyes
    • A61F2/16Intraocular lenses
    • A61F2/1691Packages or dispensers for intraocular lenses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L12/00Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
    • A61L12/08Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/18Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient
    • B65D81/22Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient in moist conditions or immersed in liquids
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D1/00Detergent compositions based essentially on surface-active compounds; Use of these compounds as a detergent
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D1/00Detergent compositions based essentially on surface-active compounds; Use of these compounds as a detergent
    • C11D1/008Polymeric surface-active agents
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16Organic compounds
    • C11D3/37Polymers
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16Organic compounds
    • C11D3/37Polymers
    • C11D3/3703Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • C11D3/3707Polyethers, e.g. polyalkyleneoxides
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D7/00Compositions of detergents based essentially on non-surface-active compounds
    • C11D7/22Organic compounds
    • C11D7/26Organic compounds containing oxygen

Definitions

  • the present invention is directed to ophthalmic compositions containing one or more block copolymers referred to as (polyoxyethylene)-(polyoxybutylene) block copolymers ("PEO-PBO").
  • PEO-PBO polyoxyethylene block copolymers
  • the invention is particularly directed to the use of PEO-
  • PBO block copolymers as wetting and/or cleaning agents in compositions for treating contact lenses.
  • Hydrogels are water swollen three-dimensional polymeric networks that are used in a variety of biomedical applications including drug delivery agents, prosthetic devices and contact lenses. It is well established that the surface characteristics of hydrogels are determined by the orientation of hydrophobic and hydrophilic moieties of the macromolecules. See, e.g., Ketelson et al., Colloids and Surfaces B: Biointerfaces, Vol. 40, pages 1-9 (2005).
  • contact lenses are in intimate contact with the corneal surface and the human tear film, which is composed of proteins, lipids, inorganic cations (e.g., calcium) and mucins
  • the biocompatibility characteristics of the lenses are directly affected by the surface wettability properties of the hydrogel materials, from which the lenses are formed.
  • evaluating the surface wettability properties of a lens material is important because such properties affect the stability of the tear film.
  • a contact lens material must have hydrophilic surface properties. If the contact lens material becomes hydrophobic, the tear film may be disrupted.
  • an aqueous solution such as human lacrimal fluid, i.e., tears
  • the contact angle is measured.
  • SiH silicone hydrogels
  • the wettability characteristics of the surfaces of contact lenses may also be modified by reducing the amount of hydrophobization on the surfaces.
  • Surfactants have been utilized in prior compositions for treating contact lenses, for example poloxamers and poloxamines, such as the Pluronic ® and Tetronic ® brands of surfactants, which are poly(oxyethylene) - poly(oxypropylene) (“PEO-PPO”) block copolymers, have been used extensively in prior products utilized to treat contact lenses. However, such surfactants do not wet SiH lenses efficiently.
  • British Patent No. 722,746 discloses surface active compounds derived from higher ⁇ , ⁇ alkylene oxides.
  • U.S. Patent No. 2,828,345 discloses hydroxypolyethylene diethers of polyoxybutylene glycols.
  • U.S. Patent No. 4,360,451 discloses amphoteric surfactant gels containing a polyoxybutylene-polyoxyethylene block copolymer.
  • the present invention is directed to the use of block copolymers referred to as (polyoxyethylene)-(polyoxybutylene) block copolymers ("PEO-PBO”) to modify the surface properties of ophthalmic medical devices, so as to enhance the wettability of the devices, and facilitate cleaning of the devices.
  • PEO-PBO block copolymers described herein may be contained in various types of compositions for treating medical devices, such as wetting solutions, soaking solutions, cleaning and comfort solutions, and disinfection solutions.
  • the present invention is particularly directed to the use of PEO-PBO copolymers in such compositions for treating contact lenses, especially SiH lenses.
  • the primary function of the PEO-PBO block copolymers in the compositions of the present invention is to treat the surface of a medical device, particularly an ophthalmic device, such as a contact lens or an intraocular lens. Such treatment facilitates the wettability of the device and/or the cleaning of the device. This surface treatment has been found to be particularly effective relative to enhancing the wettability of SiH contact lenses.
  • the block copolymers may also be utilized to: (a) enhance the antimicrobial activity of ophthalmic compositions; (b) prevent or reduce the uptake of biocides by contact lenses; (c) stabilize tear films; (d) facilitate the removal of proteins and/or lipids from the surfaces of contact lenses; (e) prevent protein and lipid deposit formation; (f) stabilize ocular emulsions; (g) prevent or reduce uptake of biocides or drugs into contact lenses or onto container surfaces; (h) function as a drug solubilizer; (i) enhance drug penetration; (j) function as comfort and cushioning agents; and/or (k) decrease the adhesion of microbes to the surfaces of contact lenses or other medical devices.
  • All of the above utilities for the block copolymers of the present invention depend on the block chemistry being used, i.e, the ratio of hydrophilic (PEO) to hydrophobic (PBO) segments.
  • the copolymers are effective at low concentrations, may be instilled directly into the eye, and are compatible with antimicrobial agents utilized to preserve aqueous pharmaceutical compositions from microbial contamination and/or to disinfect contact lenses.
  • the present invention is based in-part on a finding that PEO-PBO block copolymers can be used to effectively modify contact lens surface properties at low concentrations. More specifically, it has been discovered that the PEO-PBO block copolymers described herein are retained on hydrophobic surfaces effectively and efficiently, thereby changing the wettability of the surfaces, as reflected in improved and superior wetting properties.
  • PEO-PBO block copolymers Although there may be several reasons for this change in surface chemistry using the PEO-PBO block copolymers, it is believed that by using poly(oxybutylene) as the hydrophobic block, the surface active properties are significantly different from those of surfactants currently used in lens care products, such as poloxamers and poloxamines. It has been shown that PEO-PBO block copolymers, relative to known PEO-PPO block copolymers, such as Pluronic ® and/or Tetronic ® block copolymers, display superiority in reducing surface tension at interfaces, pack more efficiently at interfaces, have lower critical micelle concentrations and can be produced with high purity (low polydispersity).
  • a lower molecular weight block copolymer can be prepared with significant hydrophobic character.
  • the hydrophobic character of the oxybutylene provides improved interfacial properties. These properties lead to high rates of diffusion to an interface or substrate and greater retention/improved substantivity on hydrophobic surfaces, and allow lower concentrations to be used to achieve a desired property, compared to the concentrations required for PEO-PPO block copolymers such as the Pluronic® and Tetronic® brands of surfactants that have been extensively used in prior compositions for treating contact lenses.
  • a first embodiment of the present invention is directed to a method of modifying the surface of a contact lens which comprises placing the lens in an amount of a contact lens treatment solution of the type described herein sufficient to cover the lens, and soaking the lens in the solution.
  • Another embodiment is directed to a method of wetting a contact lens with said aqueous solution and to a silicone hydrogel contact lens wherein a poly(oxyethylene)-poly(oxybutylene) block copolymer is absorbed within the lens matrix and/or adsorbed to surfaces of the lens.
  • compositions comprising at least one poly(oxyethylene)-poly(oxybutylene) block copolymer of the type described herein and an ophthalmically acceptable vehicle therefor.
  • Such compositions may be formulated so as to achieve wetting of contact lenses, cleaning of contact lenses, or both wetting and cleaning of contact lenses.
  • SiH silicone hydrogel
  • PEO-PPO poly(oxyethylene)-poly(oxypropylene).
  • PEO-PBO poly(oxyethylene)-poly(oxybutylene).
  • PEO-PBO-PEO poly(oxyethylene)- poly(oxybutylene)-poly(oxyethylene).
  • PEG polyethylene glycol
  • PHMB polyhexamethylene biguanide
  • m ⁇ sm/kg means milliosmoles/kilogram of water.
  • pHEMA poly(2-hydroxyethyl methacrylate).
  • HLB hydrophilic-lipophilic balance
  • EO oxyethylene
  • contact angle is a quantitative measure of the wetting of a solid by a liquid and defined geometrically as the angle formed by a liquid where liquid, gas and solid phases intersect.
  • Alternative, related terms that may be used herein include “wetting angle” or "advancing contact angle.”
  • hydrophilic means having a strong affinity for water.
  • Alternative, related terms that may be used herein include “hydrophilicity”.
  • hydrophobic means having little or no affinity for water.
  • Alternative, related terms that may be used herein include, “hydrophobicity”.
  • pHEMA-MAA means contact lenses comprised of poly(2- hydroxy ethyl methacrylate-co-methacrylic acid).
  • Exemplary pHEMA-MAA lenses include "Acuvue® 2" (Johnson & Johnson).
  • surfactant means a substance capable of reducing the surface tension of a liquid, e.g., water or an aqueous solution, in which the substance is dissolved.
  • wetting means converting a hydrophobic surface whereon a liquid
  • uptake refers to the amount of surfactant that is absorbed and/or adsorbed by a contact lens or other medical device.
  • Alternative terms that may be used herein include, “uptake concentration”, “surfactant uptake”, “uptake results”, “uptake data” and “uptake concentration of surfactants”.
  • oxy ethylene means a two carbon alkylenyl group bonded to an oxygen atom, for example -CH 2 -CH 2 O-.
  • oxybutylene means a four carbon alkenyl group bonded to an oxygen atom, for example, -[OCH 2 C(CH 2 CH 3 )H]-.
  • block copolymer is a polymer that has at least one homopolymeric chain of one monomer and at least one additional homopolymeric chain of a second monomer. Exemplary configurations of such block copolymers include branched, star, di-block, tri-block and cyclic, wherein the cyclic configuration is preferred.
  • homopolymer means a polymer formed from a single monomer; for example, polyethylene formed by polymerization of ethylene.
  • an amount effective to preserve means an amount of an antimicrobial agent effective in producing the desired effect of preserving the solutions described herein from microbial contamination, preferably an amount which, either singly or in combination with one or more additional antimicrobial agents, is sufficient to satisfy the preservative efficacy requirements of the United States Pharmacopoeia ("USP").
  • USP United States Pharmacopoeia
  • an amount effective to disinfect means an amount of antimicrobial agent effective in producing the desired effect of disinfecting contact lenses by substantially reducing the number of viable microorganisms present on the lenses, preferably an amount which, either singly or in combination with one or more additional antimicrobial agents, is sufficient.
  • an amount effective to clean means an amount of a cleaning agent that facilitates removing, and is preferably effective to remove, debris or deposit material from a contact lens contacted with the cleaning agent containing composition.
  • ophthalmically acceptable vehicle means a pharmaceutical composition having physical properties (e.g., pH and/or osmolality) that are physiologically compatible with ophthalmic tissues.
  • the block copolymers utilized in the present invention comprise compounds that contain hydrophilic and hydrophobic segments that can be altered to control the HLB (hydrophilic-lipophilic balance), molecular weight and other properties of the block copolymers using well known anionic polymerization techniques. More particularly, the block copolymers of the present invention are those that include a poly(oxyethylene) block as the hydrophilic component and a poly(oxybutylene) block as the hydrophobic component. These may be in form of a di-block copolymer, denoted as PEO-PBO, a tri-block copolymer, represented as PEO-PBO-PEO or PBO- PEO-PBO, or other block-type configurations.
  • PEO-PBO block copolymers herein include all of the foregoing forms. These copolymers may also be described in terms of the approximate or average value assigned to the respective repeating group. For example, (EO)2o(BO)s, where the average value of the oxyethylene group is 20, and the average value of the oxybutylene group is 5.
  • Preferred polymers of the present invention are di-block copolymers of the following general formula:
  • n is an integer having an average value of 5 to 1000.
  • PEO-PBO di-block copolymers of the following general formula are particularly preferred:
  • R is selected from the group consisting of hydrogen, methyl, ethyl, propyl and butyl; m is an integer having an average value of 10 to 1000; and n is an integer having an average value of 5 to 1000.
  • PEO-PBO block copolymers utilized in the present invention have a molecular weight in the range of 1,000 to about 100,000 Daltons; and more preferably in the range of 1,000 to about 15,000 Daltons.
  • HLB hydrophilic-lipophilic balance
  • the HLB of the block co-polymers utilized in the compositions of the present invention is directly related to the solubility, surface wettability, and interfacial surface activity properties of the compositions of the present invention.
  • the BO portion of the block copolymer of formula (I) is hydrophobic and is primarily responsible for the wettability properties of the compositions described herein.
  • the EO portion of the copolymer provides the compositions with hydrophilic properties, but more importantly, it is this portion of the co-polymer that determines the aqueous solubility of the copolymers.
  • solubilizing agents in the compositions of the present invention, in which case the ratio of the EO to BO segments is somewhat less critical, it is preferred to utilize copolymers that do not require solubilizing agents, as such compounds may disrupt or modify the HLB, which in turn may adversely affect the wettability properties of the compositions, cause ocular irritation, or create other concerns.
  • the preferred copolymers of formula (I) are those wherein there is a predominance of EO to BO segments. That is, the variable "m” in formula (I) and formula (II) above is preferably greater than the variable "n".
  • the PEO-PBO block co-polymers will preferably have a ratio of EO to BO segments of from about 2 : 1 to about 10 : 1, with a ratio of about 3 : 1 to about 6:1 being most preferred.
  • PEO-PBO block copolymers may be prepared by the application or adaptation of known methods described in the literature, for example, as described in Nace, V. M. J. Am. Oil Chem. Soc. 1996, 73, 1; Yang, Z.; Pickard, S.;
  • PEO-PBO block copolymers may also be prepared by the application or adaptation of known methods described in U.S. Patent Nos. 2,828,345 (Spriggs), and 2,174,761 (Schuette et al), the entire contents of each of which are hereby incorporated into the present specification by reference.
  • PEO-PBO block copolymers described above may be synthesized using a well defined polyethylene glycol (PEG) polymer by controlled addition of oxybutylene to the primary hydroxyl group of the PEG polymer.
  • PEG polyethylene glycol
  • the PEO-PBO di-block copolymer (EO)4s(BO)io may be prepared according to the following general reaction scheme:
  • block chemistry structure may also be prepared, using techniques and methods readily available and well-known to those skilled in art.
  • reaction process may be utilized for the preparation of tri- block copolymers of the form (EO) m (BO) n (EO) m : CH 2 CH 3
  • PEO-PBO block copolymers or variations thereof may be used in combination, either with each other, or with other types of polymers.
  • PEO-PBO block copolymers or variations thereof may be used in combination with nonionic surfactants (e.g., poloxamer and poloxamine block copolymers, such as the Tetronic ® brand of surfactants available from BASF) to provide additive or synergistic effects where appropriate.
  • nonionic surfactants e.g., poloxamer and poloxamine block copolymers, such as the Tetronic ® brand of surfactants available from BASF
  • the PEO-PBO block polymers of the present invention are used in combination with poloxamine block copolymers.
  • the PEO-PBO block copolymers may also be functionalized with specific end groups for specific surface reactions to covalently bind the polymer to a surface or prepare a new polymer material.
  • PEO-PBO block copolymers that may be utilized in the present invention are not limited relative to structure or molecular weight, so long as the block copolymers are soluble in aqueous solutions and are non- toxic to ophthalmic tissue at concentrations on the order of those described herein.
  • the amount of PEO-PBO block copolymer required in the compositions of the present invention will vary depending on the particular block copolymer selected and the purpose or function for which the block copolymer is being utilized (e.g., contact lens cleaning, contact lens wetting and/or inhibition of uptake of lipids or other biomolecules), as well as on other variables, such as the identity and physical properties of other components in the compositions.
  • the determination of the ideal concentration of a particular copolymer in a given composition can be determined through routine testing.
  • Such concentrations are referred to herein by means of the function to be performed by the PEO-PBO block copolymers, such as, “an amount effective to clean”, “an amount effective to enhance wettability”, “an amount effective to inhibit the uptake of biomolecules”, and so on.
  • the total amount of PEO-PBO block copolymers contained in the compositions of the present invention will typically be in the range of 0.001 to about 1 weight/volume percent ("w/v%"), preferably about 0.05 to 0.5 w/v%, and more preferably between 0.1 to 0.2 w/v%.
  • the block copolymers of the present invention may also be combined with other components commonly utilized in products for treating contact lenses, such as rheology modifiers, enzymes, antimicrobial agents, surfactants, chelating agents, buffering agents or combinations thereof.
  • compositions may also contain one or more poly(oxyethylene)- poly(oxypropylene) block copolymers such as poloxamer or poloxamine copolymers
  • Poloxamers also known by the trade name PluronicTM, are nonionic block copolymers composed of a central hydrophobic chain of poly(oxypropylene) flanked by two hydrophilic chains of poly(oxyethylene).
  • Poloxamines also known by the trade name TetronicTM, are tetrafunctional block copolymers which contain four polyethylene oxide (PEO)-polypropylene oxide (PPO) chains joined to the nitrogen atoms of a central ethylene diamine moiety.
  • a particularly preferred embodiment of the present invention is a composition comprising a block copolymer of the formula
  • One or more of the above-described poly(oxyethylene)-poly(oxypropylene) block copolymers may be contained in the compositions of the present invention in an amount effective to facilitate wetting and/or cleaning of contact lenses, which is referred to herein as an "effective amount”.
  • an effective amount will typically be in the range of 0.001 to about 1 weight/volume percent ("w/v%"), preferably about 0.05 to 0.5 w/v%, and more preferably between 0.1 to 0.2 w/v%.
  • compositions of the present invention may contain one or more ophthalmically acceptable antimicrobial agents in an amount effective to preserve the solution from microbial contamination of the solutions or in an amount effective to disinfect contact lenses by substantially reducing the number of viable microorganisms present on the lenses.
  • ophthalmically acceptable antimicrobial agents in an amount effective to preserve the solution from microbial contamination of the solutions or in an amount effective to disinfect contact lenses by substantially reducing the number of viable microorganisms present on the lenses.
  • USP United States Pharmacopoeia
  • the invention is not limited relative to the types of antimicrobial agents that may be utilized.
  • the preferred biocides include: alkyl amidoamines, polyhexamethylene biguanide polymers ("PHMB”), polyquaternium-1, and amino biguanides, such as those described U.S. Patent No. 6,664,294.
  • the most preferred antimicrobial systems are polyquaternium-1 and a combination of polyquaternium-1 and myristamidopropyl dimethylamine ("MAPDA").
  • Amidoamines and amino alcohols may also be utilized to enhance the antimicrobial activity of the compositions described herein.
  • the preferred amidoamines are MAPDA and related compounds described in U.S. Patent No. 5,631,005 (Dassanayake, et al).
  • the preferred amino alcohols are 2-amino-2-methyl- 1-propanol ("AMP") and other amino alcohols described in U.S. Patent No. 6,319,464.
  • AMP 2-amino-2-methyl- 1-propanol
  • the entire contents of the '005 and '464 patents are hereby incorporated in the present specification by reference.
  • compositions of the present invention that are adapted for the treatment of contact lenses may include agents to enhance the cleaning or disinfection of the lenses.
  • agents may include polycarboxylates, for example, citrate, as described in U.S. Patent Nos. 5,370,744 and 5,037,647, the entire contents of each of which are hereby incorporated in the present specification by reference.
  • compositions must be sterile, aqueous, and physiologically compatible.
  • the compositions will typically have a pH in the range of 6.0 to about 9.0, and preferably in the range of 6.5 to 8.0.
  • sodium hydroxide can be used to increase the pH of the formulations, other bases such as triethanolamine, 2-amino- butanol, 2-amino-2-methyl-l-propanol (AMP) and tris(hydroxymethyl) aminomethane may also be used.
  • buffering agents may be utilized in the compositions of the present invention, such as sodium borate, boric acid, sodium citrate, citric acid, sodium bicarbonate, phosphate buffers and combinations thereof.
  • Borate and polyol systems may also be used to provide buffering, to enhance antimicrobial activity, or to provide both buffering and an enhancement of antimicrobial activity, or other useful properties to the compositions of the invention.
  • the borate and polyol systems which may be used include those described in U.S. Patent Nos. 6,849,253; 6,503,497; 6365,636; 6,143,799; 5,811,466; 5,505,953; and 5,342,620; the entire contents of each are hereby incorporated in the present specification by reference.
  • the ophthalmic compositions of the present invention will generally be formulated as sterile aqueous solutions having an osmolality of from about 200 to about 400 milliosmoles/kilogram water ("mOsm/kg") and a physiologically compatible pH.
  • the osmolality of the solutions may be adjusted by means of conventional agents, such as inorganic salts (e.g., NaCl), organic salts (e.g., sodium citrate), polyhydric alcohols (e.g., propylene glycol or sorbitol) or combinations thereof.
  • compositions may be used to treat contact lenses or other devices in accordance with processes known to those skilled in the art. More specifically, the lenses will first be removed from the eyes of the patients, and then will be immersed in the compositions of the present invention for a time sufficient to achieve the desired effect, e.g., increased wettability, cleaning and/or prevention of biocide uptake. This immersion will typically be accomplished by means of soaking the lenses in a solution for a period ranging from a few hours (e.g, approximately two to four hours) to overnight (e.g., approximately six to eight hours). The lenses will then be rinsed and placed in the eye. Prior to immersion in the said compositions, the lenses will preferably also be rinsed to facilitate cleaning.
  • compositions of the present invention may also be formulated as wetting drops that are applied directly to contact lenses while being worn by human patients.
  • the compositions may also be utilized as packaging solutions for contact lenses, i.e., solutions in which the contact lenses are stored from the time of manufacture until a sale to a contact lens wearer.
  • the lenses were then rinsed by immersion in Unisol ® saline solution (10 mL), removed from the vials, patted dry and stored in a glass vial (3 lenses per vial).
  • the uptake concentration was then measured using the dye method identified in Example 2 above. The uptake concentration was reported as the as the average of 3 lenses per lens material type.
  • the uptake results (Table 5) showed significant uptake enhancements using (EO) 4S -(BO) I4 for the silicone hydrogel lenses compared to the Tetronic ® block copolymers bearing poly(oxypropylene) as the hydrophobe block.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Mechanical Engineering (AREA)
  • Cardiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Eyeglasses (AREA)
  • Detergent Compositions (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Polyethers (AREA)
  • Materials For Medical Uses (AREA)

Abstract

The use of poly(oxyethylene)-poly(oxybutylene) block copolymers in pharmaceutical compositions useful for modifying the surfaces of contact lenses and other medical devices is disclosed. The present invention is based in-part on a discovery that this class of compounds is particularly efficient in wetting hydrophobic surfaces, such as the surfaces of silicone hydrogel contact lenses and other types of ophthalmic lenses. Such compounds are also useful for cleaning purposes. The use of the compounds as surfactants in various types of compositions for treating contact lenses therefore represents a preferred embodiment of the present invention.

Description

USE OF PEO-PBO BLOCK COPOLYMERS IN OPHTHALMIC COMPOSITIONS
Field of the Invention
The present invention is directed to ophthalmic compositions containing one or more block copolymers referred to as (polyoxyethylene)-(polyoxybutylene) block copolymers ("PEO-PBO"). The invention is particularly directed to the use of PEO-
PBO block copolymers as wetting and/or cleaning agents in compositions for treating contact lenses.
Background of the Invention
Hydrogels are water swollen three-dimensional polymeric networks that are used in a variety of biomedical applications including drug delivery agents, prosthetic devices and contact lenses. It is well established that the surface characteristics of hydrogels are determined by the orientation of hydrophobic and hydrophilic moieties of the macromolecules. See, e.g., Ketelson et al., Colloids and Surfaces B: Biointerfaces, Vol. 40, pages 1-9 (2005).
Because contact lenses are in intimate contact with the corneal surface and the human tear film, which is composed of proteins, lipids, inorganic cations (e.g., calcium) and mucins, the biocompatibility characteristics of the lenses are directly affected by the surface wettability properties of the hydrogel materials, from which the lenses are formed. In particular, evaluating the surface wettability properties of a lens material is important because such properties affect the stability of the tear film. To maintain a stable tear film, a contact lens material must have hydrophilic surface properties. If the contact lens material becomes hydrophobic, the tear film may be disrupted. To determine the wettability of a surface via an aqueous solution, such as human lacrimal fluid, i.e., tears, the contact angle is measured. The spreading of an aqueous fluid on a surface indicates that the surface is hydrophilic, thereby resulting in a low contact angle. The surface is hydrophobic if a drop of aqueous fluid does not spread, thereby resulting in a high contact angle. A new family of contact lens materials, silicone hydrogels ("SiH"), is gradually replacing traditional hydrogels as the material of choice for extended wear soft contact lenses. Silicone hydrogel materials have significantly higher oxygen permeability than traditional soft lens hydrogels due to the presence of siloxane functional groups. Additionally, the presence of siloxane groups in SiH materials results in a lens surface having hydrophobic properties. An example of a SiH lens is the Acuvue Advance® contact lenses marketed by Johnson & Johnson.
Various techniques, for example, plasma surface treatments and incorporation of molecules within the lens material, have been utilized in order to provide a biocompatible, hydrophilic and wettable lens surface. Although modifying the surface can improve biocompatibility, it has also been reported that some silicone hydrogel materials accumulate lipids over time, and that this build-up may result in a decrease in the wettability of the silicone hydrogel lens material and surface.
The wettability characteristics of the surfaces of contact lenses may also be modified by reducing the amount of hydrophobization on the surfaces. Surfactants have been utilized in prior compositions for treating contact lenses, for example poloxamers and poloxamines, such as the Pluronic® and Tetronic® brands of surfactants, which are poly(oxyethylene) - poly(oxypropylene) ("PEO-PPO") block copolymers, have been used extensively in prior products utilized to treat contact lenses. However, such surfactants do not wet SiH lenses efficiently.
British Patent No. 722,746 (Lundsted) discloses surface active compounds derived from higher α, β alkylene oxides.
U.S. Patent No. 2,828,345 (Spriggs) discloses hydroxypolyethylene diethers of polyoxybutylene glycols.
U.S. Patent No. 4,360,451 (Schmolka) discloses amphoteric surfactant gels containing a polyoxybutylene-polyoxyethylene block copolymer. In view of the foregoing, there is a need for new methods and compositions for modifϊying silicone hydrogel lens materials to impart improved surface wetting and biocompatibility characteristics during wear. The present invention is directed to satisfying this need.
Summary of the Invention
The present invention is directed to the use of block copolymers referred to as (polyoxyethylene)-(polyoxybutylene) block copolymers ("PEO-PBO") to modify the surface properties of ophthalmic medical devices, so as to enhance the wettability of the devices, and facilitate cleaning of the devices. The PEO-PBO block copolymers described herein may be contained in various types of compositions for treating medical devices, such as wetting solutions, soaking solutions, cleaning and comfort solutions, and disinfection solutions. The present invention is particularly directed to the use of PEO-PBO copolymers in such compositions for treating contact lenses, especially SiH lenses.
The primary function of the PEO-PBO block copolymers in the compositions of the present invention is to treat the surface of a medical device, particularly an ophthalmic device, such as a contact lens or an intraocular lens. Such treatment facilitates the wettability of the device and/or the cleaning of the device. This surface treatment has been found to be particularly effective relative to enhancing the wettability of SiH contact lenses.
The block copolymers may also be utilized to: (a) enhance the antimicrobial activity of ophthalmic compositions; (b) prevent or reduce the uptake of biocides by contact lenses; (c) stabilize tear films; (d) facilitate the removal of proteins and/or lipids from the surfaces of contact lenses; (e) prevent protein and lipid deposit formation; (f) stabilize ocular emulsions; (g) prevent or reduce uptake of biocides or drugs into contact lenses or onto container surfaces; (h) function as a drug solubilizer; (i) enhance drug penetration; (j) function as comfort and cushioning agents; and/or (k) decrease the adhesion of microbes to the surfaces of contact lenses or other medical devices. All of the above utilities for the block copolymers of the present invention depend on the block chemistry being used, i.e, the ratio of hydrophilic (PEO) to hydrophobic (PBO) segments. The copolymers are effective at low concentrations, may be instilled directly into the eye, and are compatible with antimicrobial agents utilized to preserve aqueous pharmaceutical compositions from microbial contamination and/or to disinfect contact lenses.
The present invention is based in-part on a finding that PEO-PBO block copolymers can be used to effectively modify contact lens surface properties at low concentrations. More specifically, it has been discovered that the PEO-PBO block copolymers described herein are retained on hydrophobic surfaces effectively and efficiently, thereby changing the wettability of the surfaces, as reflected in improved and superior wetting properties.
Although there may be several reasons for this change in surface chemistry using the PEO-PBO block copolymers, it is believed that by using poly(oxybutylene) as the hydrophobic block, the surface active properties are significantly different from those of surfactants currently used in lens care products, such as poloxamers and poloxamines. It has been shown that PEO-PBO block copolymers, relative to known PEO-PPO block copolymers, such as Pluronic® and/or Tetronic® block copolymers, display superiority in reducing surface tension at interfaces, pack more efficiently at interfaces, have lower critical micelle concentrations and can be produced with high purity (low polydispersity). By using a more hydrophobic block, i.e., oxy(butylene) versus oxy (propylene), a lower molecular weight block copolymer can be prepared with significant hydrophobic character. The hydrophobic character of the oxybutylene provides improved interfacial properties. These properties lead to high rates of diffusion to an interface or substrate and greater retention/improved substantivity on hydrophobic surfaces, and allow lower concentrations to be used to achieve a desired property, compared to the concentrations required for PEO-PPO block copolymers such as the Pluronic® and Tetronic® brands of surfactants that have been extensively used in prior compositions for treating contact lenses. The above-described characteristics of the PEO-PBO block copolymers offer significant advantages over other known block copolymers. A first embodiment of the present invention is directed to a method of modifying the surface of a contact lens which comprises placing the lens in an amount of a contact lens treatment solution of the type described herein sufficient to cover the lens, and soaking the lens in the solution. Another embodiment is directed to a method of wetting a contact lens with said aqueous solution and to a silicone hydrogel contact lens wherein a poly(oxyethylene)-poly(oxybutylene) block copolymer is absorbed within the lens matrix and/or adsorbed to surfaces of the lens.
Another embodiment is directed to ophthalmic compositions comprising at least one poly(oxyethylene)-poly(oxybutylene) block copolymer of the type described herein and an ophthalmically acceptable vehicle therefor. Such compositions may be formulated so as to achieve wetting of contact lenses, cleaning of contact lenses, or both wetting and cleaning of contact lenses.
The present invention is more fully discussed with the aid of the following figures and detailed description below.
The present invention will be better appreciated by reference to the following Detailed Description.
Detailed Description of Invention
As utilized herein, the following abbreviations and terms, unless otherwise indicated, shall be understood to have the following meanings:
The abbreviation "SiH" means silicone hydrogel.
The abbreviation "PEO-PPO" means poly(oxyethylene)-poly(oxypropylene).
The abbreviation "PEO-PBO" means poly(oxyethylene)-poly(oxybutylene).
The abbreviation "PEO-PBO-PEO" means poly(oxyethylene)- poly(oxybutylene)-poly(oxyethylene).
The abbreviation "PEG" means polyethylene glycol.
The abbreviation "b.d.l." means below detection limit.
The abbreviation "PHMB" means polyhexamethylene biguanide.
The abbreviation "mθsm/kg" means milliosmoles/kilogram of water.
The abbreviation "pHEMA" means poly(2-hydroxyethyl methacrylate).
The abbreviation "HLB" means hydrophilic-lipophilic balance.
The abbreviation "EO" means oxyethylene.
The abbreviation "BO" means oxybutylene.
The term "contact angle" is a quantitative measure of the wetting of a solid by a liquid and defined geometrically as the angle formed by a liquid where liquid, gas and solid phases intersect. Alternative, related terms that may be used herein include "wetting angle" or "advancing contact angle."
The term "hydrophilic" means having a strong affinity for water. Alternative, related terms that may be used herein include "hydrophilicity".
The term "hydrophobic" means having little or no affinity for water. Alternative, related terms that may be used herein include, "hydrophobicity".
The term "pHEMA-MAA" means contact lenses comprised of poly(2- hydroxy ethyl methacrylate-co-methacrylic acid). Exemplary pHEMA-MAA lenses include "Acuvue® 2" (Johnson & Johnson).
The term "surfactant" means a substance capable of reducing the surface tension of a liquid, e.g., water or an aqueous solution, in which the substance is dissolved.
The term "wetting" means converting a hydrophobic surface whereon a liquid
(e.g., water) does not spread because the liquid has an increased surface tension to a surface that is hydrophilic whereon the liquid spreads readily because its surface tension is reduced, as determined by a contact angle experiment. Alternative, related terms that may be used herein include "wettability".
The term "uptake" refers to the amount of surfactant that is absorbed and/or adsorbed by a contact lens or other medical device. Alternative terms that may be used herein include, "uptake concentration", "surfactant uptake", "uptake results", "uptake data" and "uptake concentration of surfactants".
The term "oxy ethylene" means a two carbon alkylenyl group bonded to an oxygen atom, for example -CH2-CH2O-.
The term "oxybutylene" means a four carbon alkenyl group bonded to an oxygen atom, for example, -[OCH2C(CH2CH3)H]-. The term "block copolymer" is a polymer that has at least one homopolymeric chain of one monomer and at least one additional homopolymeric chain of a second monomer. Exemplary configurations of such block copolymers include branched, star, di-block, tri-block and cyclic, wherein the cyclic configuration is preferred.
The term "homopolymer" means a polymer formed from a single monomer; for example, polyethylene formed by polymerization of ethylene.
The term "an amount effective to preserve" means an amount of an antimicrobial agent effective in producing the desired effect of preserving the solutions described herein from microbial contamination, preferably an amount which, either singly or in combination with one or more additional antimicrobial agents, is sufficient to satisfy the preservative efficacy requirements of the United States Pharmacopoeia ("USP").
The term "an amount effective to disinfect" means an amount of antimicrobial agent effective in producing the desired effect of disinfecting contact lenses by substantially reducing the number of viable microorganisms present on the lenses, preferably an amount which, either singly or in combination with one or more additional antimicrobial agents, is sufficient.
The term "an amount effective to clean" means an amount of a cleaning agent that facilitates removing, and is preferably effective to remove, debris or deposit material from a contact lens contacted with the cleaning agent containing composition.
The term "ophthalmically acceptable vehicle" means a pharmaceutical composition having physical properties (e.g., pH and/or osmolality) that are physiologically compatible with ophthalmic tissues.
The block copolymers utilized in the present invention comprise compounds that contain hydrophilic and hydrophobic segments that can be altered to control the HLB (hydrophilic-lipophilic balance), molecular weight and other properties of the block copolymers using well known anionic polymerization techniques. More particularly, the block copolymers of the present invention are those that include a poly(oxyethylene) block as the hydrophilic component and a poly(oxybutylene) block as the hydrophobic component. These may be in form of a di-block copolymer, denoted as PEO-PBO, a tri-block copolymer, represented as PEO-PBO-PEO or PBO- PEO-PBO, or other block-type configurations. Unless expressly indicated to the contrary, all references to "PEO-PBO block copolymers" herein include all of the foregoing forms. These copolymers may also be described in terms of the approximate or average value assigned to the respective repeating group. For example, (EO)2o(BO)s, where the average value of the oxyethylene group is 20, and the average value of the oxybutylene group is 5.
Preferred polymers of the present invention are di-block copolymers of the following general formula:
(EO)1n(BO)n (I)
wherein m is an integer having an average value of 10 to 1000 and n is an integer having an average value of 5 to 1000.
PEO-PBO di-block copolymers of the following general formula are particularly preferred:
Figure imgf000010_0001
wherein R is selected from the group consisting of hydrogen, methyl, ethyl, propyl and butyl; m is an integer having an average value of 10 to 1000; and n is an integer having an average value of 5 to 1000.
Most preferred is a copolymer of formula (II) wherein R is methyl; m has an average value of 45; and n has an average value of 10. The PEO-PBO block copolymers utilized in the present invention have a molecular weight in the range of 1,000 to about 100,000 Daltons; and more preferably in the range of 1,000 to about 15,000 Daltons.
Maintaining a proper hydrophilic-lipophilic balance (HLB) imparts certain properties to the PEO-PBO block co-polymer compositions of the present invention.
For example, the HLB of the block co-polymers utilized in the compositions of the present invention is directly related to the solubility, surface wettability, and interfacial surface activity properties of the compositions of the present invention.
The BO portion of the block copolymer of formula (I) is hydrophobic and is primarily responsible for the wettability properties of the compositions described herein. The EO portion of the copolymer provides the compositions with hydrophilic properties, but more importantly, it is this portion of the co-polymer that determines the aqueous solubility of the copolymers. Although it is possible to utilize solubilizing agents in the compositions of the present invention, in which case the ratio of the EO to BO segments is somewhat less critical, it is preferred to utilize copolymers that do not require solubilizing agents, as such compounds may disrupt or modify the HLB, which in turn may adversely affect the wettability properties of the compositions, cause ocular irritation, or create other concerns. Therefore, the preferred copolymers of formula (I) are those wherein there is a predominance of EO to BO segments. That is, the variable "m" in formula (I) and formula (II) above is preferably greater than the variable "n". The PEO-PBO block co-polymers will preferably have a ratio of EO to BO segments of from about 2 : 1 to about 10 : 1, with a ratio of about 3 : 1 to about 6:1 being most preferred.
The foregoing PEO-PBO block copolymers may be prepared by the application or adaptation of known methods described in the literature, for example, as described in Nace, V. M. J. Am. Oil Chem. Soc. 1996, 73, 1; Yang, Z.; Pickard, S.;
Deng, N.-J.; Barlow, R. J.; Attwood, D.; Booth, C. Macromolecules 1994, 27, 2371;
Yang, Y.-W.; Deng, N.-J.; Yu, G.-E.; Zhou, Z.-K.; Attwood, D.; Booth, C. Langmuir
1995, 11, 4703; Yu, G.-E.; Yang, Y.-W.; Yang, Z.; Attwood, D.; Booth, C; Nace, V. M. Langmuir 1996, 12, 3404; Chaibundit, C; Mai, S.-M.; Heatley, F.; Booth, C. Langmuir 2000, 16, 9645; Bedells, A. D.; Arafeh, R. M.; Yang, Z.; Attwood, D.; Heatley, F.; Pedget, J. C; Price, C; Booth, C. J. Chem. Soc. Faraday Trans. 1993, 89, 1235; and Kelarakis, A.; Havredaki, V.; Yu, G.-E.; Derici, L.; Booth, C. Macromolecules 1998, 31, 944, the entire contents of each of which are hereby incorporated in the present specification by reference. The foregoing PEO-PBO block copolymers may also be prepared by the application or adaptation of known methods described in U.S. Patent Nos. 2,828,345 (Spriggs), and 2,174,761 (Schuette et al), the entire contents of each of which are hereby incorporated into the present specification by reference.
The PEO-PBO block copolymers described above may be synthesized using a well defined polyethylene glycol (PEG) polymer by controlled addition of oxybutylene to the primary hydroxyl group of the PEG polymer. For example, the PEO-PBO di-block copolymer (EO)4s(BO)io may be prepared according to the following general reaction scheme:
Figure imgf000012_0001
CH3O(CH2CH2)m+/K+ CH3(OCH2CH2UOCH2 H
H
Other variations of the block chemistry structure may also be prepared, using techniques and methods readily available and well-known to those skilled in art. For example, the following reaction process may be utilized for the preparation of tri- block copolymers of the form (EO)m(BO)n(EO)m: CH2CH3
/ °χ CH2CH3 K+/H+OCHOCHOΗ+/K+ + (n- I) CH2 CH K+/H+OCH2CHO)n " H+/K+
CH2CH3
Figure imgf000013_0001
-► KW (OCH2CH2O)m(CH2CHO)n(CH2CH2O)mΗ+/K+ 1-t ► Triblock copolymer: (EO)m(BO)n(EO)m
The above-described block copolymers and variations thereof may be used in combination, either with each other, or with other types of polymers. For example, PEO-PBO block copolymers or variations thereof may be used in combination with nonionic surfactants (e.g., poloxamer and poloxamine block copolymers, such as the Tetronic® brand of surfactants available from BASF) to provide additive or synergistic effects where appropriate. In a preferred embodiment, the PEO-PBO block polymers of the present invention are used in combination with poloxamine block copolymers. The PEO-PBO block copolymers may also be functionalized with specific end groups for specific surface reactions to covalently bind the polymer to a surface or prepare a new polymer material. The PEO-PBO block copolymers that may be utilized in the present invention are not limited relative to structure or molecular weight, so long as the block copolymers are soluble in aqueous solutions and are non- toxic to ophthalmic tissue at concentrations on the order of those described herein.
The amount of PEO-PBO block copolymer required in the compositions of the present invention will vary depending on the particular block copolymer selected and the purpose or function for which the block copolymer is being utilized (e.g., contact lens cleaning, contact lens wetting and/or inhibition of uptake of lipids or other biomolecules), as well as on other variables, such as the identity and physical properties of other components in the compositions. The determination of the ideal concentration of a particular copolymer in a given composition can be determined through routine testing. Such concentrations are referred to herein by means of the function to be performed by the PEO-PBO block copolymers, such as, "an amount effective to clean", "an amount effective to enhance wettability", "an amount effective to inhibit the uptake of biomolecules", and so on.
The total amount of PEO-PBO block copolymers contained in the compositions of the present invention will typically be in the range of 0.001 to about 1 weight/volume percent ("w/v%"), preferably about 0.05 to 0.5 w/v%, and more preferably between 0.1 to 0.2 w/v%.
The block copolymers of the present invention may also be combined with other components commonly utilized in products for treating contact lenses, such as rheology modifiers, enzymes, antimicrobial agents, surfactants, chelating agents, buffering agents or combinations thereof.
The compositions may also contain one or more poly(oxyethylene)- poly(oxypropylene) block copolymers such as poloxamer or poloxamine copolymers
(e.g., poloxamine 1304, which is commercially available as "Tetronic® 1304").
Poloxamers, also known by the trade name Pluronic™, are nonionic block copolymers composed of a central hydrophobic chain of poly(oxypropylene) flanked by two hydrophilic chains of poly(oxyethylene). Poloxamines, also known by the trade name Tetronic™, are tetrafunctional block copolymers which contain four polyethylene oxide (PEO)-polypropylene oxide (PPO) chains joined to the nitrogen atoms of a central ethylene diamine moiety. A particularly preferred embodiment of the present invention is a composition comprising a block copolymer of the formula
C2H5 CH3(OCH2CH2)45(OCH2CH)10OH (m)
and poloxamine 1304.
One or more of the above-described poly(oxyethylene)-poly(oxypropylene) block copolymers may be contained in the compositions of the present invention in an amount effective to facilitate wetting and/or cleaning of contact lenses, which is referred to herein as an "effective amount". Such amount will typically be in the range of 0.001 to about 1 weight/volume percent ("w/v%"), preferably about 0.05 to 0.5 w/v%, and more preferably between 0.1 to 0.2 w/v%.
The compositions of the present invention may contain one or more ophthalmically acceptable antimicrobial agents in an amount effective to preserve the solution from microbial contamination of the solutions or in an amount effective to disinfect contact lenses by substantially reducing the number of viable microorganisms present on the lenses. The levels of antimicrobial activity required to preserve ophthalmic compositions from microbial contamination or to disinfect contact lenses are well known to those skilled in the art, based both on personal experience and official, published standards, such as those set forth in the United
States Pharmacopoeia ("USP") relative to preservative efficacy, and EN ISO 14729 :
2001 relative to contact lens disinfection, and similar publications.
The invention is not limited relative to the types of antimicrobial agents that may be utilized. The preferred biocides include: alkyl amidoamines, polyhexamethylene biguanide polymers ("PHMB"), polyquaternium-1, and amino biguanides, such as those described U.S. Patent No. 6,664,294. The most preferred antimicrobial systems are polyquaternium-1 and a combination of polyquaternium-1 and myristamidopropyl dimethylamine ("MAPDA").
Amidoamines and amino alcohols may also be utilized to enhance the antimicrobial activity of the compositions described herein. The preferred amidoamines are MAPDA and related compounds described in U.S. Patent No. 5,631,005 (Dassanayake, et al). The preferred amino alcohols are 2-amino-2-methyl- 1-propanol ("AMP") and other amino alcohols described in U.S. Patent No. 6,319,464. The entire contents of the '005 and '464 patents are hereby incorporated in the present specification by reference.
The compositions of the present invention that are adapted for the treatment of contact lenses may include agents to enhance the cleaning or disinfection of the lenses. Such agents may include polycarboxylates, for example, citrate, as described in U.S. Patent Nos. 5,370,744 and 5,037,647, the entire contents of each of which are hereby incorporated in the present specification by reference.
The compositions must be sterile, aqueous, and physiologically compatible. The compositions will typically have a pH in the range of 6.0 to about 9.0, and preferably in the range of 6.5 to 8.0. Although sodium hydroxide can be used to increase the pH of the formulations, other bases such as triethanolamine, 2-amino- butanol, 2-amino-2-methyl-l-propanol (AMP) and tris(hydroxymethyl) aminomethane may also be used.
A variety of buffering agents may be utilized in the compositions of the present invention, such as sodium borate, boric acid, sodium citrate, citric acid, sodium bicarbonate, phosphate buffers and combinations thereof. Borate and polyol systems may also be used to provide buffering, to enhance antimicrobial activity, or to provide both buffering and an enhancement of antimicrobial activity, or other useful properties to the compositions of the invention. The borate and polyol systems which may be used include those described in U.S. Patent Nos. 6,849,253; 6,503,497; 6365,636; 6,143,799; 5,811,466; 5,505,953; and 5,342,620; the entire contents of each are hereby incorporated in the present specification by reference.
The ophthalmic compositions of the present invention will generally be formulated as sterile aqueous solutions having an osmolality of from about 200 to about 400 milliosmoles/kilogram water ("mOsm/kg") and a physiologically compatible pH. The osmolality of the solutions may be adjusted by means of conventional agents, such as inorganic salts (e.g., NaCl), organic salts (e.g., sodium citrate), polyhydric alcohols (e.g., propylene glycol or sorbitol) or combinations thereof.
The above-described compositions may be used to treat contact lenses or other devices in accordance with processes known to those skilled in the art. More specifically, the lenses will first be removed from the eyes of the patients, and then will be immersed in the compositions of the present invention for a time sufficient to achieve the desired effect, e.g., increased wettability, cleaning and/or prevention of biocide uptake. This immersion will typically be accomplished by means of soaking the lenses in a solution for a period ranging from a few hours (e.g, approximately two to four hours) to overnight (e.g., approximately six to eight hours). The lenses will then be rinsed and placed in the eye. Prior to immersion in the said compositions, the lenses will preferably also be rinsed to facilitate cleaning. However, the compositions of the present invention may also be formulated as wetting drops that are applied directly to contact lenses while being worn by human patients. The compositions may also be utilized as packaging solutions for contact lenses, i.e., solutions in which the contact lenses are stored from the time of manufacture until a sale to a contact lens wearer.
The present invention may be better understood by reference to the following examples, which are provided to further illustrate certain preferred embodiments of the invention, and should in no way be construed as limiting the scope of the invention. In the following Example, various methods known to one skilled in the art may be employed to measure the contact angle for lenses according to the present invention. Exemplary methods include, but are not limited to, the Sessile method or the Captive Bubble method.
EXAMPLE 1
Contact Angle Measurements for Control Lenses: No Pre-Soaking
The contact angles for pHEMA-MAA lenses (Acuvue2®) and silicone hydrogel lenses (Acuvue Advance®, O2 Optix® and Pure Vision®), none having been exposed to a pre-soak treatment in a surfactant solution, were measured as described in this Example 1. The contact angle results are reported in Table 1 below, will hereinafter be referred to as the "Control Lens Results."
Four different brands of contact lenses (one pHEMA-MAA lens type: Acuvue 2®; and three silicon hydrogel lens types: Acuvue Advance®, C^Optix® and Pure
Vision®) were soaked in Unisol® saline solution overnight to remove residual packing solution contaminants, prior to measuring the contact angles. The contact angle of each lens was then measured according to the Sessile drop method, as described below, at room temperature, i.e, 23 C ± 0.5. The results are presented in Table 1, below.
Sessile drop method A video based contact angle measuring system (OCA 20) from Future Digital
Scientific employing SCA20 software (Version 2.1.5 buildlβ) was used. An accelerated approach was developed to evaluate the lens surface wettability over a specific time period. The pHEMA-MAA lenses were subjected to sequential wetting and air exposure cycles to simulate the clinical contact lens wetting and drying conditions that occur during the normal blinking process. One "cycle" means that a lens was soaked in saline solution for 5 minutes, followed by an exposure of the lens to air for 1.5 minutes. The contact angles of a water droplet on the pHEMA-MAA surface were measured within 10 seconds following each cycle. In all measurements, the left and right contact angles were determined and the mean of these contact angles was used. For each drop image, three independent fitting measurements were performed to provide three mean contact angles of the same drop image. The average of these three contact angles was determined and the precision was within ± 3°. This procedure was repeated on three new pHEMA-MAA lenses to confirm the reproducibility of the method.
Table 1
Figure imgf000019_0001
The above data demonstrate that the contact angle for all lens types increases as the number of cycles increases. The high contact angles observed for Acuvue 2®, Acuvue Advance® and Pure Vision® indicate that the surfaces of these lenses were hydrophobic and displayed poor wetting properties towards water.
EXAMPLE 2 Amount of Tetronic® 1304 and (EO)45-(BO)I4 Uptake by pHEMA-MAA
(Acuvue2®) and Silicone Hydrogel (Acuvue Advance®) Lenses After a Pre-Soak in Surfactant Solutions A, B and C
All contact lenses were soaked in UnisolR saline solution overnight to remove residual packing solution contaminants. Surfactant solutions A, B and C were prepared by dissolving each of the formulation components, as shown in Table 2 below, in water. Into a clean glass vial, one lens of each type (i.e., one Acuvue 2® one Acuvue Advance®) was taken directly from the pack and pre-soaked in 10 ml of each surfactant solution for 24 hours. The lenses were then removed from the solutions and blotted dry. The lenses were then rinsed by immersion in Unisol® saline solution (10 niL), removed from the vials, patted dry and stored in a glass vial. The uptake concentration was then measured using the dye method as reported in Ketelson et al, Colloids and Surfaces Biointerfaces, vol. 40, pages 1-9 (2005). The uptake concentration of Tetronic® 1304 in Acuvue Advance® silicone hydrogel lenses, treated with formulation A was below detection limit (b.d.L). The other results are shown in Table 2 below:
Table 2 Contact Lens Uptake of Tetronic® 1304 and (EO)45-(BO)i4
Figure imgf000020_0001
The above data demonstrate that significant levels of Tetronic R 1304 and (EO)45-(BO)i4 were measured in both Acuvue 2® and Acuvue Advance® lenses. In particular, (EO)4S-(BO)I4 was found to have significant uptake for the Acuvue Advance® (silicone hydrogel) lens, as demonstrated by the results obtained with formulations B and C, whereas there was no detectable uptake of Tetronic® 1304 by the Acuvue Advance® silicone hydrogel lenses treated with formulation A. EXAMPLE 3
Contact Angle Measurements for Acuvue 2® (pHEMA-MAA) and Various Silicone Hydrogel Lenses After a Pre-Soak in 0.1% (EO)45-(BO)I4
Solution (in Unisol®)
All contact lenses were soaked in Unisol R saline solution overnight to remove residual packing solution contaminants. The lenses were then pre-soaked for 24 hours in a 0.1% (EO)45-(BO)i4 solution (in Unisol®). The contact angle of each lens was then measured according to the Sessile drop method, as described above in Example 1, at room temperature, i.e, 23 C ± 0.5.
Table 3
Figure imgf000021_0001
The above data demonstrate that the contact angle for all lens types decreases relative to the control lenses (see Example 1 above). Pre-soaking the lenses in a 0.1% (EO)45-(BO)i4 solution in Unisol® saline reduced the contact angles, indicating that the surfaces of all lens types were more wettable towards water compared to their original surface properties. EXAMPLE 4 Contact Angle Measurements for Acuvue 2 (pHEMA-MAA) and Various
Silicone Hydrogel Lenses After a Pre-Soak in a Binary Surfactant Solution containing 0.1% (EO)45-(BO)I4 and 0.1% Tetronic® 1304 (in Unisol®)
All contact lenses were soaked in Unisol® saline solution overnight, to remove residual packing solution contaminants. The lenses were then presoaked for 24 hours in a binary surfactant solution containing 0.1% (EO)45-(BO)i4 and 0.1% Tetronic®1304 (in Unisol® saline). The contact angle of each lens was then measured according to the Sessile drop method, as described above in Example 1, at room temperature, i.e, 23 C ± 0.5.
Table 4
Figure imgf000022_0001
The above data demonstrate that the contact angles for all lens types decreased relative to the control lenses (see Example 1). Pre-soaking the lenses in the binary solution containing both (EO)45-(BO)i4 and 0.1% Tetronic® 1304 led to a significant reduction in the contact angles across all lens types, thereby improving wettability of the lenses.
EXAMPLE 5 Amount of Tetronic® 1304, Tetronic® 1107, (EO)45(BO)i4 and (EO)20(BO)5
Uptake by pHEMA-MAA (Acuvue 2®) and Silicone Hydrogel (Acuvue Advance®, O2 Optix® and Pure Vision®) Lenses After a Pre-Soak in Surfactant
Solutions A, B, C and D
Three lenses of each type were soaked in Unisol® saline solution overnight to remove residual packing solution contaminants. Surfactant solutions A, B, C and D were prepared by dissolving each of the formulation components, as shown in Table 5 below, in Unisol® saline solution. Into a clean glass vial, three lenses of each type (i.e., Acuvue 2® Acuvue Advance®, O2 Optix® and Pure Vision®) were taken directly from the pack and pre-soaked in 10 mL of each surfactant solution. The lenses were then removed from the solutions and blotted dry. The lenses were then rinsed by immersion in Unisol® saline solution (10 mL), removed from the vials, patted dry and stored in a glass vial (3 lenses per vial). The uptake concentration was then measured using the dye method identified in Example 2 above. The uptake concentration was reported as the as the average of 3 lenses per lens material type. The uptake results (Table 5) showed significant uptake enhancements using (EO)4S-(BO)I4 for the silicone hydrogel lenses compared to the Tetronic® block copolymers bearing poly(oxypropylene) as the hydrophobe block.
Table 5
Figure imgf000024_0001
Figure imgf000024_0002
The above data demonstrate significant uptake enhancements upon using (EO)45-(BO)14 for the most hydrophobic silicone hydrogel lenses (Pure Vision® and Acuvue Advance®). These results demonstrate the ability of PEO-PBO block copolymers to interact strongly with hydrophobic surfaces. The improved wettability of the silicone hydrogel lenses (see Examples 3 and 4) is believed to reflect the presence of the PEO-PBO block copolymer at the surface of the lens materials. EXAMPLE 6
Contact Angle Measurements for Acuvue 2 (pHEMA-MAA) and Acuvue
Advance® after a Pre-Soak in a Binary Surfactant Solution containing 0.10A
(EO)45-(BO)I0 and 0.05% Tetronic® 1304 (in Unisol®)
All contact lenses were soaked in Unisol® saline solution overnight, to remove residual packing solution contaminants. The lenses were then presoaked for 24 hours in surfactant solutions containing either: 0.05% Tetronic®1304 (Formulation A); or 0.1% (EO)45-(BO)io and 0.05% Tetronic®1304 (Formulation B). The contact angle of each lens was then measured according to the Sessile drop method, as described above in Example 1, at room temperature, i.e, 23 C ± 0.5.
Table 6
Figure imgf000025_0001
Figure imgf000026_0001
The above data demonstrate that the contact angles for the Acuvue 2 lens type decreased for both Formulation A and B relative to control lenses. However, pre- soaking the Acuvue Advance lenses in the solution containing 0.05% Tetronic® 1304 (Formulation A) showed relatively elevated contact angles. Comparatively, soaking the Acuvue Advance lenses in the binary solution (Formulation B) containing both 0.1% (EO)45-(BO)io and 0.05% Tetronic® 1304 led to a significant reduction in the contact angle, thereby improving wettability of the lenses.

Claims

CLAIMSWe Claim:
1. An ophthalmic composition comprising an effective amount of at least one poly(oxyethylene)-poly(oxybutylene) block copolymer having a molecular weight in the range of 500 to 100,000 Daltons and an ophthalmically acceptable vehicle therefor.
2. A composition according to claim 1, wherein the poly(oxyethylene)- poly(oxybutylene) block copolymer is of the formula (EO)1n(BO)n, wherein m is an integer having an average value of 10 to 1000 and n is an integer having an average value of 5 to 1000.
3. A composition according to claim 2, wherein m is greater than n.
4. A composition according to claim 3, wherein the ratio of m to n is in the range of about 2 : 1 to about 10 : 1.
5. A composition according to claim 4, wherein the ratio of m to n is in the range of about 3 : 1 to about 6:1.
6. A composition according to claim 5, wherein the average value of m is 45 and the average value of n is 10.
7. A composition according to claim 1, wherein the poly(oxyethylene)- poly(oxybutylene) block copolymer has a molecular weight in the range of 1,000 to 50,000 Daltons.
8. A composition according to claim 7, wherein the poly(oxyethylene)- poly(oxybutylene) block copolymer has a molecular weight in the range of 2,000 to 10,000 Daltons.
9. A composition according claim 1, wherein the poly(oxyethylene)- poly(oxybutylene) block copolymer is of the formula
Figure imgf000028_0001
wherein R is selected from the group consisting of hydrogen, methyl, ethyl, propyl and butyl; m is an integer having an average value of 10 to 1000; and n is an integer having an average value of 5 to 1000.
10. A composition according to claim 9, wherein R is methyl; m has an average value of 45; and n has an average value of 10.
11. A composition according to claim 1 , further comprising an effective amount of a poly(oxyethylene)-poly(oxypropylene) block copolymer.
12. A composition according to claim 11, wherein the poly(oxyethylene)- poly(oxybutylene) block copolymer comprises poloxamine 1304.
13. A composition according to claim 1, wherein the composition is a sterile aqueous solution for treating a contact lens, said solution having an osmolality of 200 to 400 milliosmoles/kilogram.
14. A composition according to claim 13, further comprising an ophthalmically acceptable antimicrobial agent in an amount effective to disinfect a contact lens.
15. A composition according to claim 14, wherein said antimicrobial agent comprises polyquaternium-1.
16. A composition according to claim 1, wherein the solution contains said block copolymer at a concentration of 0.001 to 1% w/v.
17. A composition according to claim 16, wherein the block copolymer concentration is 0.05% to 0.5% w/v.
18. A composition according to claim 17, wherein the block copolymer concentration is 0.1% to 0.2% w/v.
19. A composition according to claim 18, wherein the block copolymer concentration is 0.1% w/v.
20. A method of treating a contact lens to modify the surface characteristics of the lens or clean the lens, which comprises applying an effective amount of a composition according to any one of claims 1-19 to the lens.
PCT/US2007/087012 2006-12-11 2007-12-10 Use of peo-pbo block copolymers in ophthalmic compositions Ceased WO2008073909A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
AU2007333187A AU2007333187B2 (en) 2006-12-11 2007-12-10 Use of PEO-PBO block copolymers in ophthalmic compositions
EP07869093A EP2092047B1 (en) 2006-12-11 2007-12-10 Ophthalmic compositions comprising peo-pbo block copolymers
PL07869093T PL2092047T3 (en) 2006-12-11 2007-12-10 Ophthalmic compositions comprising peo-pbo block copolymers
DK07869093.0T DK2092047T3 (en) 2006-12-11 2007-12-10 Ophthalmic compositions comprising PEO-PBO copolymers
MX2009005533A MX2009005533A (en) 2006-12-11 2007-12-10 Use of peo-pbo block copolymers in ophthalmic compositions.
BRPI0720063-3A BRPI0720063B1 (en) 2006-12-11 2007-12-10 Ophthalmic composition comprising depoli (oxyethylene) -poly (oxybutylene) block copolymer
SI200730476T SI2092047T1 (en) 2006-12-11 2007-12-10 Ophthalmic compositions comprising peo-pbo block copolymers
CA2671376A CA2671376C (en) 2006-12-11 2007-12-10 Use of peo-pbo block copolymers in ophthalmic compositions
CN2007800456173A CN101611127B (en) 2006-12-11 2007-12-10 Use of PEO-PBO block copolymers in ophthalmic compositions
AT07869093T ATE489450T1 (en) 2006-12-11 2007-12-10 OPHTHALMIC COMPOSITIONS CONTAINING PEO-PBO BLOCK COPOLYMERS
HK09108266.1A HK1132292B (en) 2006-12-11 2007-12-10 Ophthalmic compositions comprising peo-pbo block copolymers
NZ577237A NZ577237A (en) 2006-12-11 2007-12-10 Use of peo-pbo block copolymers in ophthalmic compositions
DE602007010823T DE602007010823D1 (en) 2006-12-11 2007-12-10 OPHTHALMIC COMPOSITIONS CONTAIN PEO-PBO BLOCK COPOLYMERS
JP2009540519A JP5124590B2 (en) 2006-12-11 2007-12-10 Use of PEO-PBO block copolymers in ophthalmic compositions
KR1020097013065A KR101378368B1 (en) 2006-12-11 2007-12-10 Use of peo-pbo block copolymers in ophthalmic compositions
NO20092036A NO340419B1 (en) 2006-12-11 2009-05-26 Sterile aqueous ophthalmic preparation comprising PEO-PBO block copolymers and a method of treating a contact lens

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86951306P 2006-12-11 2006-12-11
US60/869,513 2006-12-11

Publications (3)

Publication Number Publication Date
WO2008073909A2 true WO2008073909A2 (en) 2008-06-19
WO2008073909A3 WO2008073909A3 (en) 2008-07-31
WO2008073909B1 WO2008073909B1 (en) 2008-09-18

Family

ID=39427514

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/087012 Ceased WO2008073909A2 (en) 2006-12-11 2007-12-10 Use of peo-pbo block copolymers in ophthalmic compositions

Country Status (23)

Country Link
US (3) US8318144B2 (en)
EP (1) EP2092047B1 (en)
JP (2) JP5124590B2 (en)
KR (1) KR101378368B1 (en)
CN (1) CN101611127B (en)
AR (1) AR064211A1 (en)
AT (1) ATE489450T1 (en)
AU (1) AU2007333187B2 (en)
BR (1) BRPI0720063B1 (en)
CA (1) CA2671376C (en)
CY (1) CY1111523T1 (en)
DE (1) DE602007010823D1 (en)
DK (1) DK2092047T3 (en)
ES (1) ES2354393T3 (en)
MX (1) MX2009005533A (en)
NO (1) NO340419B1 (en)
NZ (1) NZ577237A (en)
PL (1) PL2092047T3 (en)
PT (1) PT2092047E (en)
SI (1) SI2092047T1 (en)
TW (1) TWI434926B (en)
WO (1) WO2008073909A2 (en)
ZA (1) ZA200903368B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012532878A (en) * 2009-07-07 2012-12-20 アルコン リサーチ, リミテッド Ophthalmic ethylene oxide butylene oxide block copolymer composition
US9591850B2 (en) 2013-09-27 2017-03-14 Novartis Ag Compositions and methods for disinfecting and cleaning contact lenses

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI434926B (en) * 2006-12-11 2014-04-21 Alcon Res Ltd Use of peo-pbo block copolymers in ophthalmic compositions
US20080151181A1 (en) * 2006-12-20 2008-06-26 Bausch & Lomb Incorporated Coatings and Solutions for Contact Lenses
TW201127423A (en) 2009-12-17 2011-08-16 Alcon Res Ltd Ophthalmic solutions with improved disinfection profiles
JP5794744B2 (en) 2010-05-05 2015-10-14 アルコン リサーチ, リミテッド Stabilized ophthalmic galactomannan formulation
WO2011153349A1 (en) 2010-06-02 2011-12-08 Alcon Research, Ltd. Ophthalmic compositions comprising pbo-peo-pbo block copolymers
ES2423914T3 (en) 2010-07-30 2013-09-25 Novartis Ag Silicone hydrogel lenses with water-rich surfaces
SG11201400228WA (en) 2011-10-12 2014-05-29 Novartis Ag Method for making uv-absorbing ophthalmic lenses by coating
TW201336527A (en) 2012-02-10 2013-09-16 Alcon Res Ltd Aqueous pharmaceutical composition with enhanced stability
CN104871036B (en) 2012-12-17 2019-12-10 诺华股份有限公司 Method for making improved UV-absorbing ophthalmic lenses
WO2014209939A2 (en) * 2013-06-24 2014-12-31 Novartis Ag Lens care product for ozone-based cleaning/disinfecting of contact lenses
CN103387663B (en) * 2013-07-29 2016-02-17 山东理工大学 Prepare the method for end group containing the amphipathic nature block polymer of sulfydryl
US10167387B2 (en) 2013-09-10 2019-01-01 Colorado State University Research Foundation Synthetic polymeric materials and devices thereof
HUE038809T2 (en) 2013-12-17 2018-11-28 Novartis Ag A silicone hydrogel lens with a crosslinked hydrophilic coating
JP6273039B2 (en) 2014-04-03 2018-01-31 ノバルティス アーゲー Electrochemical system for disinfecting and cleaning contact lenses
US10398799B2 (en) 2014-04-03 2019-09-03 Novartis Ag System for disinfecting contact lenses
EP3186070B1 (en) 2014-08-26 2019-09-25 Novartis AG Method for applying stable coating on silicone hydrogel contact lenses
US10245324B2 (en) 2014-10-31 2019-04-02 Johnson & Johnson Consumer Inc. Ophthalmic composition
CN105173319B (en) * 2015-09-25 2018-04-13 福州市辰翔家居制造有限公司 A kind of polyhedral and its construction method
CN105288631B (en) * 2015-11-17 2018-10-30 杭州普施康生物科技有限公司 A kind of new anticancer drug nanometer formulation and preparation method thereof
WO2017093834A1 (en) * 2015-12-03 2017-06-08 Novartis Ag Contact lens packaging solutions
KR102604468B1 (en) 2015-12-15 2023-11-22 알콘 인코포레이티드 Method for applying stable coatings on silicone hydrogel contact lenses
US10632202B2 (en) 2016-03-04 2020-04-28 Johnson & Johnson Consumer Inc. Preservative containing compositions
WO2018069816A1 (en) 2016-10-11 2018-04-19 Novartis Ag Polymerizable polydimethylsiloxane-polyoxyalkylene block copolymers
CN106955369A (en) * 2017-05-22 2017-07-18 陶圣香 A kind of preparation method of contact lens care solution
WO2018224975A1 (en) 2017-06-07 2018-12-13 Novartis Ag Silicone hydrogel contact lenses
CN111164129B (en) * 2017-08-16 2024-03-12 昭荣化学工业株式会社 PEG-based ligands with enhanced dispersion and improved properties
US11129862B2 (en) 2017-08-30 2021-09-28 Johnson & Johnson Consumer Inc. Ophthalmic compositions
SE541313C2 (en) * 2017-10-13 2019-06-25 Amferia Ab Amphiphilic antimicrobial hydrogel
US10830923B2 (en) 2017-12-13 2020-11-10 Alcon Inc. Method for producing MPS-compatible water gradient contact lenses
GB201813229D0 (en) 2018-08-14 2018-09-26 Ocutec Ltd Formulation
TWI757773B (en) 2019-06-28 2022-03-11 瑞士商愛爾康公司 Ophthalmic compositions
WO2021124099A1 (en) * 2019-12-16 2021-06-24 Alcon Inc. Wettable silicone hydrogel contact lenses
HUE067883T2 (en) 2020-03-19 2024-11-28 Alcon Inc Method for producing embedded or hybrid hydrogel contact lenses
WO2022097049A1 (en) 2020-11-04 2022-05-12 Alcon Inc. Method for making photochromic contact lenses
EP4240578B1 (en) 2020-11-04 2024-12-18 Alcon Inc. Method for making photochromic contact lenses
CN112716895A (en) * 2020-12-18 2021-04-30 济南大学 Andrographolide drug-loaded micelle of Pluronic F127 modified based on phenylbutyric acid and preparation method thereof
US12049606B2 (en) 2021-01-12 2024-07-30 Johnson & Johnson Vision Care, Inc. Compositions for ophthalmologic devices
CN113088411A (en) * 2021-04-08 2021-07-09 山西利普达医药科技有限公司 Eye washing and inactivating virus composition containing polyquaternium-1 and application thereof
CN117716262A (en) 2021-09-01 2024-03-15 爱尔康公司 Method for producing wettable silicone hydrogel contact lenses
WO2023187672A1 (en) 2022-03-31 2023-10-05 Alcon Inc. Ophthalmic compositions
KR20240163713A (en) 2022-05-09 2024-11-19 알콘 인코포레이티드 Method for manufacturing an embedded hydrogel contact lens
US20240165019A1 (en) 2022-11-21 2024-05-23 Bausch + Lomb Ireland Limited Methods for Treating Eyetear Film Deficiency
TW202439971A (en) 2022-12-21 2024-10-16 美商壯生和壯生視覺關懷公司 Compositions for ophthalmologic devices
TW202434214A (en) 2022-12-21 2024-09-01 美商壯生和壯生視覺關懷公司 Compositions for ophthalmologic devices
WO2024134384A1 (en) 2022-12-21 2024-06-27 Johnson & Johnson Vision Care, Inc. Compositions for ophthalmologic devices
WO2024134383A1 (en) 2022-12-21 2024-06-27 Johnson & Johnson Vision Care, Inc. Compositions for ophthalmologic devices
TW202500366A (en) 2023-03-22 2025-01-01 瑞士商愛爾康公司 Method for making embedded hydrogel contact lenses
US20250277076A1 (en) 2024-03-04 2025-09-04 Alcon Inc. Mucoadhesive hydrophilic copolymers and uses thereof
US20250362530A1 (en) 2024-05-22 2025-11-27 Alcon Inc. Method for making centrally colored contact lenses
WO2026042047A1 (en) 2024-08-23 2026-02-26 Johnson & Johnson Vision Care, Inc. Compositions and articles comprising reversible complexes of crosslinked carrageenan

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB722746A (en) 1952-06-24 1955-01-26 Wyandotte Chemicals Corp Surface active compounds derived from higher ª‡, ª‰ alkylene oxides
US2828345A (en) 1955-04-27 1958-03-25 Dow Chemical Co Hydroxypolyoxyethylene diethers of polyoxybutylene glycols
US4360451A (en) 1981-08-10 1982-11-23 Basf Wyandotte Corporation Amphoteric surfactant gels
US5773396A (en) 1993-06-18 1998-06-30 Polymer Technology Corporation Contact lens cleaning and wetting solutions containing a non-amine polyethyleneocy adduct having a HLB value of at least about 18, a surface active agent having a HLB of less than 18, and wetting agent
US20020141899A1 (en) 2000-09-28 2002-10-03 Fu-Pao Tsao Compositions and methods for cleaning contact lenses
WO2003043668A2 (en) 2001-11-21 2003-05-30 Novartis Ag Conditioning solution for contact lenses

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2174761A (en) 1935-04-13 1939-10-03 Ig Farbenindustrie Ag Condensation products derived from hydroxy compounds and method of producing them
US2674619A (en) 1953-10-19 1954-04-06 Wyandotte Chemicals Corp Polyoxyalkylene compounds
US3050511A (en) 1958-09-15 1962-08-21 Dow Chemical Co Block copolymers of alkenyl aromatic hydrocarbons and alkylene oxides
US3829506A (en) 1971-06-01 1974-08-13 Basf Wyandotte Corp Biodegradable surface active agents having good foam properties and foam stabilizing characteristics
US4130517A (en) 1973-01-29 1978-12-19 Exxon Research & Engineering Co. Multiphase block and graft copolymers comprising a hydrophilic continuous phase and hydrophobic domains
CA1043039A (en) 1973-01-29 1978-11-21 Robert D. Lundberg Multiphase block and graft copolymers comprising a hydrophilic continuous phase and hydrophobic domains
US4104824A (en) 1975-02-27 1978-08-08 Exxon Research & Engineering Co. Multiphase block and graft copolymers comprising a hydrophilic continuous phase and hydrophobic domains
US4104825A (en) * 1976-10-18 1978-08-08 Young Windows Inc. Vent
US4326977A (en) * 1980-11-10 1982-04-27 Basf Wyandotte Corporation Liquid antiseptic cleaners with improved foaming properties
US4504405A (en) * 1980-12-18 1985-03-12 Smith And Nephew Associated Companies P.L.C. Method of cleaning soft contact lenses
PT89126B (en) 1987-12-02 1993-09-30 Colgate Palmolive Co A process for the preparation of a soft cleansing and conditioning composition for skin lotion comprising low levels of a nonionic active agent and an organic acid
US5037647A (en) 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
EP0394400B1 (en) 1988-09-22 1995-07-12 University of Utah Polymer supersurfactants for protein resistance and protein removal
FR2662830B1 (en) * 1990-06-05 1992-08-28 Bull Sa PROCESS FOR DIALOGUE BETWEEN PROCESSORS OF A SYSTEM, SYSTEM FOR ITS IMPLEMENTATION AND USE FOR THE DISTRIBUTION OF PROCESSES TO PROCESSORS.
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
US5346703A (en) 1990-08-07 1994-09-13 Mediventures, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
US5376693A (en) * 1990-08-07 1994-12-27 Mediventures Inc. Thermo-irreversible gel corneal contact lens formed in situ
CA2132826C (en) 1992-05-06 1999-01-05 Masood Chowhan Use of borate-polyol complexes in ophthalmic compositions
US5505953A (en) 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
US5370744B1 (en) 1993-08-27 1999-11-09 Alcon Lab Inc Process for cleaning and disinfecting contact lenses
US5631005A (en) 1994-09-21 1997-05-20 Alcon Laboratories, Inc. Use of amidoamines in ophthalmic compositions
EP0698660B1 (en) 1994-08-22 2001-09-26 Kao Corporation Detergent composition for hard surface
US6004923A (en) 1995-10-27 1999-12-21 Basf Aktiengesellschaft Fatty acid derivatives and their use as surfactants in detergents and cleaners
JP4030603B2 (en) 1995-11-02 2008-01-09 ノボザイムス アクティーゼルスカブ Alkaline protease, method for producing the same, use and microorganism producing the protease
PT948357E (en) 1996-12-13 2002-10-31 Alcon Lab Inc USE OF ALCOHOLS OF LOW MOLECULAR WEIGHT IN OPHTHALMIC COMPOSITIONS
US6214596B1 (en) * 1996-12-18 2001-04-10 Alcon Laboratories, Inc. Liquid enzyme compositions and methods of use in contact lens cleaning and disinfecting systems
PE65999A1 (en) * 1997-09-02 1999-07-27 Novartis Ag PROCESS FOR THE MANUFACTURE OF A MOLDED ITEM
US20030129083A1 (en) * 1997-11-26 2003-07-10 Advanced Medical Optics, Inc. Multi purpose contact lens care compositions including propylene glycol or glycerin
ZA9811445B (en) 1997-12-19 1999-08-16 Alcon Lab Inc Aminobiguanides and the use thereof to disinfect contact lenses and preserve pharmaceutical compositions.
US6656504B1 (en) 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
DE10241878A1 (en) 2002-09-10 2004-03-11 Ecolab Gmbh & Co. Ohg Vehicle cleaner, used e.g. for removing firmly-adhering metal dust or metal grindings residue or cleaning rims, contains complex-forming polyamino- or polycarboxylic acids or salt
US7378479B2 (en) 2002-09-13 2008-05-27 Lubrizol Advanced Materials, Inc. Multi-purpose polymers, methods and compositions
US20040241130A1 (en) 2002-09-13 2004-12-02 Krishnan Tamareselvy Multi-purpose polymers, methods and compositions
US7282178B2 (en) 2005-06-03 2007-10-16 Bausch & Lomb Incorporated Composition and method for cleaning lipid deposits on contact lenses
TWI434926B (en) * 2006-12-11 2014-04-21 Alcon Res Ltd Use of peo-pbo block copolymers in ophthalmic compositions

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB722746A (en) 1952-06-24 1955-01-26 Wyandotte Chemicals Corp Surface active compounds derived from higher ª‡, ª‰ alkylene oxides
US2828345A (en) 1955-04-27 1958-03-25 Dow Chemical Co Hydroxypolyoxyethylene diethers of polyoxybutylene glycols
US4360451A (en) 1981-08-10 1982-11-23 Basf Wyandotte Corporation Amphoteric surfactant gels
US5773396A (en) 1993-06-18 1998-06-30 Polymer Technology Corporation Contact lens cleaning and wetting solutions containing a non-amine polyethyleneocy adduct having a HLB value of at least about 18, a surface active agent having a HLB of less than 18, and wetting agent
US20020141899A1 (en) 2000-09-28 2002-10-03 Fu-Pao Tsao Compositions and methods for cleaning contact lenses
WO2003043668A2 (en) 2001-11-21 2003-05-30 Novartis Ag Conditioning solution for contact lenses

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012532878A (en) * 2009-07-07 2012-12-20 アルコン リサーチ, リミテッド Ophthalmic ethylene oxide butylene oxide block copolymer composition
US9175249B2 (en) 2009-07-07 2015-11-03 Alcon Research, Ltd. Ethyleneoxide butyleneoxide block copolymer compositions
US9591850B2 (en) 2013-09-27 2017-03-14 Novartis Ag Compositions and methods for disinfecting and cleaning contact lenses

Also Published As

Publication number Publication date
EP2092047B1 (en) 2010-11-24
US20110059039A1 (en) 2011-03-10
NO340419B1 (en) 2017-04-18
HK1132292A1 (en) 2010-02-19
JP2013065026A (en) 2013-04-11
PL2092047T3 (en) 2011-06-30
MX2009005533A (en) 2009-06-12
AU2007333187A1 (en) 2008-06-19
US8318144B2 (en) 2012-11-27
CA2671376C (en) 2013-04-30
BRPI0720063A2 (en) 2014-11-25
TW200839346A (en) 2008-10-01
EP2092047A2 (en) 2009-08-26
US20170114300A1 (en) 2017-04-27
AR064211A1 (en) 2009-03-18
CA2671376A1 (en) 2008-06-19
ES2354393T3 (en) 2011-03-14
ZA200903368B (en) 2010-08-25
DE602007010823D1 (en) 2011-01-05
AU2007333187B2 (en) 2012-11-08
PT2092047E (en) 2011-01-11
CN101611127A (en) 2009-12-23
CN101611127B (en) 2013-04-17
NZ577237A (en) 2010-11-26
BRPI0720063B1 (en) 2017-08-01
NO20092036L (en) 2009-06-30
DK2092047T3 (en) 2011-01-03
US9574160B2 (en) 2017-02-21
JP5554818B2 (en) 2014-07-23
JP2010512546A (en) 2010-04-22
WO2008073909A3 (en) 2008-07-31
TWI434926B (en) 2014-04-21
ATE489450T1 (en) 2010-12-15
US10584307B2 (en) 2020-03-10
SI2092047T1 (en) 2011-02-28
KR101378368B1 (en) 2014-04-10
JP5124590B2 (en) 2013-01-23
US20080138310A1 (en) 2008-06-12
WO2008073909B1 (en) 2008-09-18
CY1111523T1 (en) 2015-08-05
KR20090088419A (en) 2009-08-19

Similar Documents

Publication Publication Date Title
US10584307B2 (en) Use of PEO-PBO block copolymers in ophthalmic compositions
US9521842B2 (en) Use of PBO-PEO-PBO block copolymers in ophthalmic compositions
AU2013200591B2 (en) Use of peo-pbo block copolymers in ophthalmic compositions
CA2920286C (en) Compositions and methods for disinfecting and cleaning contact lenses
HK1132292B (en) Ophthalmic compositions comprising peo-pbo block copolymers

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780045617.3

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2007333187

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007869093

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/005533

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 577237

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2671376

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009540519

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2007333187

Country of ref document: AU

Date of ref document: 20071210

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020097013065

Country of ref document: KR

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07869093

Country of ref document: EP

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: PI0720063

Country of ref document: BR

Free format text: ESCLARECA A OMISSAO DE "NATHANIEL D. MCQUEEN" DO QUADRO DE INVENTORES, UMA VEZ QUE O MESMO CONSTA NA PUBLICACAO WO 2008/073909 DE 19/06/2008.

ENP Entry into the national phase

Ref document number: PI0720063

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090610